[Misunderstandings without limits].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Jak Jervell.
Explore the source record for details and available documents.
BACKGROUND: Few studies have directly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors in persons with type 2 diabetes. METHODS: In this prospective, multicenter, double-blind, five-year study, we randomly assigned 250 subjects with type 2 diabetes and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg daily, in 120 subjects) or the ACE inhibitor enalapril (20 mg daily, in 130 subjects). The primary end point was the change in the glomerular filtration rate (determined by measuring the plasma clearance of iohexol) between the baseline value and the last available value during the five-year treatment period. Secondary end points included the annual changes in the glomerular filtration rate, serum creatinine level, urinary albumin excretion, and blood pressure; the rates of end-stage renal disease and cardiovascular events; and the rate of death from all causes. RESULTS: After five years, the change in the glomerular filtration rate was -17.5 ml per minute per 1.73 m2 (where the minus sign denotes a decrement) in the telmisartan-treated subjects, as compared with -15.0 ml per minute per 1.73 m2 in the enalapril-treated subjects; the treatment difference was thus -2.6 ml per minute per 1.73 m2 (95 percent confidence interval, -7.1 to 2.0 ml per minute per 1.73 m2)[corrected] The lower boundary of the confidence interval, in favor of enalapril, was greater than the predefined margin of -10.0 ml per minute per 1.73 m2, indicating that telmisartan was not inferior to enalapril. The effects of the two agents on the secondary end points were not significantly different after five years. CONCLUSIONS: Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes. These findings do not necessarily apply to persons with more advanced nephropathy, but they support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in persons with conditions that place them at high risk for cardiovascular events.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
BACKGROUND: The purpose of this study was to investigate the distribution and association of selected risk factors for diabetes mellitus in a semi-rural Palestinian village. MATERIAL/METHODS: We performed a cross-sectional, population-based study of 500 adults aged 30 to 65 in a semi-rural Palestinian village. The study included two phases: a household survey and an individual assessment utilizing the oral glucose tolerance test OGTT to determine the diabetes status of the participants, anthropometric measurements for body mass index (BMI) and waist-hip ratio (WHR), blood biochemistry measurements for lipids, blood pressure measurement, and a standard questionnaire to assess demographic and other factors. RESULTS: The association between various risk factors and diabetes status was explored by comparing statistical means and proportions and crude and adjusted odds ratios (OR). A multivariate logistic regression using sex and seven factors initially found to be significantly associated with diabetes identified four factors that remained significantly associated with diabetes after adjustment for age and sex. The four main factors are age (OR = 1.08, 95%CI = 1.05-1.12), positive family history of diabetes (OR = 3.09, 95%CI = 1.53-6.24), triglycerides (OR = 1.006, 95%CI = 1.002-1.009), and WHR (OR = 2.13, 95%CI =1.31-3.45). CONCLUSIONS: Two factors associated with diabetes are potentially modifiable in this Palestinian population: WHR and triglyceride levels. These should be addressed by preventive health activities, including health promotion. The association between diabetes and age supports the conclusion that the prevalence of diabetes is expected to increase with the aging of the population.